trending Market Intelligence /marketintelligence/en/news-insights/trending/4JENKPjQIqeV1oB-WNdSyA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Dova Pharmaceuticals appoints president/CEO, chief commercial officer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Dova Pharmaceuticals appoints president/CEO, chief commercial officer

Dova Pharmaceuticals Inc. appointed David Zaccardelli president and CEO, and also named Jason Hoitt chief commercial officer.

Zaccardelli — who was previously acting CEO of Cempra Pharmaceuticals Inc. until the company's merger with Melinta Therapeutics Inc. — is replacing Alex Sapir in the president and CEO roles.

Hoitt was previously vice president and head of U.S. sales at Insmed Inc. and head of U.S. sales and senior director of medical affairs at Sarepta Therapeutics Inc.

Dova expects the appointments of Zaccardelli and Hoitt to accelerate the launch of the company's bleeding disorder drug Doptelet. The therapy was approved by the U.S. Food and Drug Administration in May to treat thrombocytopenia, a condition characterized by an abnormally low platelet count, in adults with chronic liver disease.

Dova is also seeking the U.S. FDA's approval for Doptelet as a therapy for immune thrombocytopenia, a bleeding disorder that can lead to excessive bruising and bleeding due to low levels of platelets in the blood.